08.28.2018 Issue 416

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Blog: Where do Literature Reviews Go Awry?

Monday, August 28

Beginning May 26, 2020, literature reviews will play a key role throughout CERS under new MEDDEV regulations, including in the establishment of state of the art, according to a tHEORetically Speaking blog post by Evidence Partners' Susan Sykes.

Senate OKs Measure to Require Price Disclosure in Drug Ads

ICER Using New Economic Modeling Platform for Value Assessment

Big Hopes, Obstacles for Blockchain Tech

A Look at Some Drugmakers that Froze Price Increases

ICER Releases Report on Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer

Quantzig Whitepaper Looks at RWE’s Value in Health Care

Study: Russian Trolls Stoked Vaccine Debates

Cigna, Express Scripts Shareholders OK $67B Acquisition


Associate Director Health Economics

Associate Director Real World Evidence (RWE) and Epidemiology

Associate Director/ Director, Medical Affairs- HEOR

Watson Health - Outcomes Research Leader (HEOR)

Senior Research Analyst - HEOR

Senior Director, HEOR Oncology & Specialty - 1850018301

Adjunct Faculty, Economics of Health Care, on-line

Watson Health - Lead Research Analyst (Outcomes Research)

Industry Spotlight



Conferences Webinars
6th Annual Real-World Analytics Summit 2018
    September 1-2, Boston, Massachusetts

ESMO Academy 2018
    September 1-3, Oxford, U.K.

Identifying Evidence for NICE Economic Submissions
    September 5, York, U.K.

22nd Annual Merck Technology Symposium
    September 5-6, Long Branch, New Jersey

ISPOR Asia Pacific 2018
    September 8-11, Tokyo, Japan

The Next Generation PSP: How to Maximize Patient Outcomes and Boost Patient Experience Through More Advance PSP Design
    August 30

Compliance Considerations in Medical/Commercial Collaborations
    August 30

HIPAA Texting and Emailing: Myths vs Realities
    September 5

Building the Digital Infrastructure to Enable Genetic Medicine: Recommendations from a Multi-Stakeholder Summit
    September 7


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Blockchain: Transformational Change for Pharma?

Benchmarking Market Access Strategies for High-Cost Drugs and Biologics

HTA in Europe: Key Success Factors for Positive HTA Recommendations

Paying for Digital Health: Payer Insights

Benchmarking Pharma’s MSL Capabilities

Biosimilars: U.S. Payer Perspectives

The Worth of Real World Evidence in Healthcare

A Holistic Approach to Payment Accuracy Helps Drive Cost Savings

Improving Patient Matching with a Simple Plug-In

Real-World Evidence in the Cloud: How Technology is Revealing the Big Picture in Pharma

How Payers Can Save an Average of $25,579 Per Patient by Eliminating Unwarranted, Non-Evidence-Based Cancer Treatment

ICER’s Reference Case for Economic Evaluations: Principles and Rationale


Special Thanks to Our Partners:
            Evidera   HealthCore     University of FL
      Xcenda  OM1    Parexel   Jefferson   Dymaxium
      Precision Xtract    Pharmerit    eMax Health   Sciformix
      Evidence Partners    ICON    Truven